CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial. The vaccine – developed by researchers at the ...

Glioblastoma multiforme (GBM) is associated with a poor ... to assess the safety and immunogenicity of a dendritic cell-based vaccine targeting the EGFRvIII antigen. The study included patients ...

CVGBM, an investigational cancer vaccine, induced T-cell responses in patients with MGMT-unmethylated glioblastoma.

ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

MimiVax, Inc. and UI Pharmaceuticals are proud to announce the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP's recently qualified ...

People with glioblastoma who took part in the study lived more than twice as long as those on standard treatments in many cases, researchers say. The vaccine works by using the body's immune cells ...

Glioblastoma (GBM) is a fast growing and aggressive ... neurosurgeon Robert Fenstermaker began their work on the SurVaxM vaccine at Roswell Park Comprehensive Cancer Center. Ciesielski and ...